Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab with Chemo-Radiation in Stage IIIA-IIIB NSCLC
NCT00460551Phase 2Terminated
- Sponsor
- Genmab
- Start
- Apr 2007
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of zalutumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genmab. Primary endpoint: Progression Free Survival Verified by Imaging Techniques. Started Apr 2007; status: terminated.
02
Drugs
zalutumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00460551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00460551.